TSHA

Taysha Gene Therapies has seen sharp swings in its share price over recent years, and that volatility puts a spotlight on a basic question for holders: Is the market value you see on screen today in line with what its balance sheet and book value can…

Taysha Gene Therapies reported phase 1/2 REVEAL data in Rett syndrome, where all 10 participants receiving a single intrathecal TSHA-102 dose gained or regained at least one developmental milestone and no treatment-related serious adverse events were observed.

Taysha Gene Therapies has delivered a 90.1% gain over the past three years, which puts fresh attention on whether that kind of move is backed up by the value on its balance sheet.

Taysha Gene Therapies (TSHA) has drawn fresh attention after a period of pressure on the share price, with the stock roughly flat over the past day but lower over the past month and the past three months.

TSHA-102 dosing complete in pivotal Rett syndrome trials with 100% responder rate.

Taysha Gene Therapies (TSHA) drew fresh investor attention after reporting a 100% overall response rate in early TSHA-102 Rett syndrome trial data, expanding its Catalent manufacturing agreement, and outlining cash coverage into late 2028.

Moby summary of Taysha Gene Therapies, Inc.'s Q2 2026 earnings call

Company reports 100% response rate in Part A trial, completes pivotal dosing, and maintains $455.4 million cash position into 2028

Taysha Gene Therapies (NASDAQ:TSHA) said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential biologics license application submission.

Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6‑month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027 TSHA-102 continues to be…

DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc.